Nuformix plc (LON:NFX – Get Free Report)’s share price was down 10% on Monday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). Approximately 1,986,748 shares were traded during trading, a decline of 82% from the average daily volume of 10,762,529 shares. The stock had previously closed at GBX 0.05 ($0.00).
Nuformix Stock Performance
The stock has a market cap of £368,689.50, a price-to-earnings ratio of -1.63 and a beta of 1.22. The firm has a fifty day moving average of GBX 0.05 and a 200 day moving average of GBX 0.12. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- Insider Selling Explained: Can it Inform Your Investing Choices?
- These 3 Quirky ETFs May Be Strong Plays in 2025
- What is the S&P/TSX Index?
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
